ATAD3A-related pontocerebellar hypoplasia: new patients and insights into phenotypic variability.
ATAD3A
Mitochondria
OXPHOS
Pontocerebellar hypoplasia
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
24 04 2023
24 04 2023
Historique:
received:
02
12
2022
accepted:
02
04
2023
medline:
26
4
2023
pubmed:
25
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Pathogenic variants in the ATAD3A gene lead to a heterogenous clinical picture and severity ranging from recessive neonatal-lethal pontocerebellar hypoplasia through milder dominant Harel-Yoon syndrome up to, again, neonatal-lethal but dominant cardiomyopathy. The genetic diagnostics of ATAD3A-related disorders is also challenging due to three paralogous genes in the ATAD3 locus, making it a difficult target for both sequencing and CNV analyses. Here we report four individuals from two families with compound heterozygous p.Leu77Val and exon 3-4 deletion in the ATAD3A gene. One of these patients was characterized as having combined OXPHOS deficiency based on decreased complex IV activities, decreased complex IV, I, and V holoenzyme content, as well as decreased levels of COX2 and ATP5A subunits and decreased rate of mitochondrial proteosynthesis. All four reported patients shared a strikingly similar clinical picture to a previously reported patient with the p.Leu77Val variant in combination with a null allele. They presented with a less severe course of the disease and a longer lifespan than in the case of biallelic loss-of-function variants. This consistency of the phenotype in otherwise clinically heterogenous disorder led us to the hypothesis that the severity of the phenotype could depend on the severity of variant impact. To follow this rationale, we reviewed the published cases and sorted the recessive variants according to their impact predicted by their type and the severity of the disease in the patients. The clinical picture and severity of ATAD3A-related disorders are homogenous in patients sharing the same combinations of variants. This knowledge enables deduction of variant impact severity based on known cases and allows more accurate prognosis estimation, as well as a better understanding of the ATAD3A function.
Sections du résumé
BACKGROUND
Pathogenic variants in the ATAD3A gene lead to a heterogenous clinical picture and severity ranging from recessive neonatal-lethal pontocerebellar hypoplasia through milder dominant Harel-Yoon syndrome up to, again, neonatal-lethal but dominant cardiomyopathy. The genetic diagnostics of ATAD3A-related disorders is also challenging due to three paralogous genes in the ATAD3 locus, making it a difficult target for both sequencing and CNV analyses.
RESULTS
Here we report four individuals from two families with compound heterozygous p.Leu77Val and exon 3-4 deletion in the ATAD3A gene. One of these patients was characterized as having combined OXPHOS deficiency based on decreased complex IV activities, decreased complex IV, I, and V holoenzyme content, as well as decreased levels of COX2 and ATP5A subunits and decreased rate of mitochondrial proteosynthesis. All four reported patients shared a strikingly similar clinical picture to a previously reported patient with the p.Leu77Val variant in combination with a null allele. They presented with a less severe course of the disease and a longer lifespan than in the case of biallelic loss-of-function variants. This consistency of the phenotype in otherwise clinically heterogenous disorder led us to the hypothesis that the severity of the phenotype could depend on the severity of variant impact. To follow this rationale, we reviewed the published cases and sorted the recessive variants according to their impact predicted by their type and the severity of the disease in the patients.
CONCLUSION
The clinical picture and severity of ATAD3A-related disorders are homogenous in patients sharing the same combinations of variants. This knowledge enables deduction of variant impact severity based on known cases and allows more accurate prognosis estimation, as well as a better understanding of the ATAD3A function.
Identifiants
pubmed: 37095554
doi: 10.1186/s13023-023-02689-3
pii: 10.1186/s13023-023-02689-3
pmc: PMC10127305
doi:
Substances chimiques
ATPases Associated with Diverse Cellular Activities
EC 3.6.4.-
ATAD3A protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2023. The Author(s).
Références
Am J Hum Genet. 2016 Oct 6;99(4):831-845
pubmed: 27640307
Med. 2021 Jan 15;2(1):49-73
pubmed: 33575671
Methods Enzymol. 2009;456:321-39
pubmed: 19348897
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Mitochondrion. 2012 Jul;12(4):441-8
pubmed: 22664726
Hum Mutat. 2018 Nov;39(11):1517-1524
pubmed: 30192042
Clin Chim Acta. 1994 Jul;228(1):35-51
pubmed: 7955428
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nucleic Acids Res. 2012 Jul;40(13):6109-21
pubmed: 22453275
Biochem J. 2004 Nov 1;383(Pt. 3):561-71
pubmed: 15265003
Cell Rep. 2021 Dec 21;37(12):110139
pubmed: 34936866
Mol Cell Biol. 2010 Apr;30(8):1984-96
pubmed: 20154147
Mol Endocrinol. 2012 Nov;26(11):1868-82
pubmed: 22973050
Mol Genet Metab. 2020 Sep - Oct;131(1-2):107-113
pubmed: 32933822
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Hum Mol Genet. 2017 Apr 15;26(8):1432-1443
pubmed: 28158749
Genome Med. 2021 Apr 12;13(1):55
pubmed: 33845882
Nat Immunol. 2018 Jan;19(1):29-40
pubmed: 29242539
Archaea. 2016 Sep 14;2016:9294307
pubmed: 27703410
Anal Biochem. 1991 Dec;199(2):223-31
pubmed: 1812789
Neurology. 1968 Mar;18(3):299
pubmed: 5690395
J Proteomics. 2013 Feb 21;79:219-30
pubmed: 23313214
Nat Commun. 2019 Mar 26;10(1):1371
pubmed: 30914652
Mol Genet Metab. 2019 Dec;128(4):452-462
pubmed: 31727539
Brain. 2017 Jun 1;140(6):1595-1610
pubmed: 28549128
Brain. 2017 Nov 1;140(11):e67
pubmed: 29053800
Genome Med. 2019 Dec 31;12(1):3
pubmed: 31892348
Brain. 2017 Nov 1;140(11):e66
pubmed: 29053797
Endocr Regul. 2018 Apr 1;52(2):110-118
pubmed: 29715184
PLoS Comput Biol. 2013;9(7):e1003153
pubmed: 23874191
Am J Hum Genet. 2020 Feb 6;106(2):272-279
pubmed: 32004445
Biol Rev Camb Philos Soc. 2018 May;93(2):827-844
pubmed: 28941010